Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Quest Diagnostics IncTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Recursion Pharmaceuticals Inc — how do they compare? Quest Diagnostics Inc trades at $237.44 (market cap $26.21B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Quest Diagnostics Inc is far larger — about 14.5× Recursion Pharmaceuticals Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

DGXRXRX
Market Cap
$26.21B$1.81B
Sector
HealthHealth
52-Week High
$238.50$6.79
52-Week Low
$173.49$2.84
Enterprise Value
$31.97B$1.33B
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.

The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.

Recursion Pharmaceuticals Inc

RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.

Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX